Darren R Feldman1. 1. aGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center bDepartment of Medicine, Weill Medical College of Cornell University, New York, New York, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this study is to update the reader on advances in postpubertal male germ cell tumours (GCTs) over the last 18 months. RECENT FINDINGS: Single nucleotide polymorphisms, including in four sex-determination genes, have been identified as additional genetic susceptibility loci to testicular GCT development. New insights into cisplatin resistance implicate the PDGFR-PIK3CA-AKT and RAS pathways. Circulating tumour cells and circulating microRNAs are potential new biomarkers. In clinical stage I (CS-I) GCT, two large studies have confirmed the excellent outcomes achieved with surveillance, which is now the management option of choice for CS I-A nonseminoma and all CS-I seminomas; CS I-B nonseminoma remains controversial. First-line trials of dose-dense multidrug regimens reported promising results but have not yet supplanted BEPx4. Survivorship issues, including secondary malignancies from chemotherapy, remain important in this disease and are a continuing focus of ongoing research. SUMMARY: Important research questions remain across all aspects of GCT. The next decade is likely to produce many new and exciting discoveries that will benefit GCT patients.
PURPOSE OF REVIEW: The purpose of this study is to update the reader on advances in postpubertal male germ cell tumours (GCTs) over the last 18 months. RECENT FINDINGS: Single nucleotide polymorphisms, including in four sex-determination genes, have been identified as additional genetic susceptibility loci to testicular GCT development. New insights into cisplatin resistance implicate the PDGFR-PIK3CA-AKT and RAS pathways. Circulating tumour cells and circulating microRNAs are potential new biomarkers. In clinical stage I (CS-I) GCT, two large studies have confirmed the excellent outcomes achieved with surveillance, which is now the management option of choice for CS I-A nonseminoma and all CS-I seminomas; CS I-B nonseminoma remains controversial. First-line trials of dose-dense multidrug regimens reported promising results but have not yet supplanted BEPx4. Survivorship issues, including secondary malignancies from chemotherapy, remain important in this disease and are a continuing focus of ongoing research. SUMMARY: Important research questions remain across all aspects of GCT. The next decade is likely to produce many new and exciting discoveries that will benefit GCT patients.
Authors: Bárbara Vilela-Salgueiro; Daniela Barros-Silva; João Lobo; Ana Laura Costa; Rita Guimarães; Mariana Cantante; Paula Lopes; Isaac Braga; Jorge Oliveira; Rui Henrique; Carmen Jerónimo Journal: Philos Trans R Soc Lond B Biol Sci Date: 2018-06-05 Impact factor: 6.237
Authors: Klaus-Peter Dieckmann; Arlo Radtke; Lajos Geczi; Cord Matthies; Petra Anheuser; Ulrike Eckardt; Jörg Sommer; Friedemann Zengerling; Emanuela Trenti; Renate Pichler; Hanjo Belz; Stefan Zastrow; Alexander Winter; Sebastian Melchior; Johannes Hammel; Jennifer Kranz; Marius Bolten; Susanne Krege; Björn Haben; Wolfgang Loidl; Christian Guido Ruf; Julia Heinzelbecker; Axel Heidenreich; Jann Frederik Cremers; Christoph Oing; Thomas Hermanns; Christian Daniel Fankhauser; Silke Gillessen; Hermann Reichegger; Richard Cathomas; Martin Pichler; Marcus Hentrich; Klaus Eredics; Anja Lorch; Christian Wülfing; Sven Peine; Werner Wosniok; Carsten Bokemeyer; Gazanfer Belge Journal: J Clin Oncol Date: 2019-03-15 Impact factor: 44.544